Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy
Authors:
- Satoshi ShigenoSSSatoshi Shigeno
- Takahiro KodamaTakahiro Kodama
- Kazuhiro MuraiKMKazuhiro Murai
- Emi SometaniESEmi Sometani
- Kentaro YasudaKYKentaro Yasuda
- Yuki TahataYTYuki Tahata
- Akira NishioANAkira Nishio
- Satoshi TanakaSTSatoshi Tanaka
- Masanori MiyazakiMMMasanori Miyazaki
- Kazuyoshi OhkawaKazuyoshi Ohkawa
- Naruyasu KakitaNKNaruyasu Kakita
- Seiichi TawaraSTSeiichi Tawara
Open Access
- 26 May 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Abstract
Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.Keywords
This publication has 31 references indexed in Scilit:
- Early inhibition of hepatocyte innate responses by hepatitis B virusJournal of Hepatology, 2015
- Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in miceJournal of Hepatology, 2015
- Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and AdefovirThe Journal of Infectious Diseases, 2015
- Association of Interleukin-1β and Gene Polymorphisms with Liver Pathogenesis in Hepatitis B Virus Infection among Eastern Indian PopulationJournal of Clinical and Experimental Hepatology, 2013
- Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)Journal of Biological Chemistry, 2013
- Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen SeroconvertersGastroenterology, 2011
- Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in MiceGastroenterology, 2010
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004